Mumps

An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)

Also Known As:

Networked: 2475 relevant articles (84 outcomes, 210 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Measles
2.	Rubella (German Measles)
3.	Chickenpox
4.	Warts (Wart)
5.	Infection

Experts

1.	Centers for Disease Control and Prevention (CDC): 33 articles (06/2015 - 02/2000)
2.	Poland, Gregory A: 22 articles (09/2013 - 03/2002)
3.	Jacobson, Robert M: 19 articles (09/2013 - 03/2002)
4.	Bellini, William J: 15 articles (01/2015 - 09/2007)
5.	Ovsyannikova, Inna G: 15 articles (02/2012 - 05/2003)
6.	Vierkant, Robert A: 13 articles (11/2011 - 03/2002)
7.	Kuter, Barbara J: 12 articles (04/2015 - 06/2002)
8.	Rota, Paul A: 10 articles (08/2015 - 09/2007)
9.	Jacobsen, Steven J: 10 articles (05/2014 - 03/2002)
10.	Klein, Nicola P: 9 articles (02/2015 - 04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mumps:

1.	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 07/01/1998 - "The new MMR vaccine 'Priorix' containing the new RIT 4385 mumps strain was safe and had a significantly improved local tolerability profile over the comparator vaccine, M-M-R II, while eliciting an at least equivalent immune response." 04/19/2012 - "Our study indicates that the mumps component of the MMR vaccine offered adequate protection against mumps among schoolchildren. " 05/01/2014 - "Low vaccine efficacy of mumps component among MMR vaccine recipients in Chennai, India." 01/01/2007 - "The recently observed improvement in the epidemiological situation of mumps (trend towards lower and less frequent epidemic peaks) reflect the use of measles-mumps-rubella vaccine which was increasingly acquired by parents at their own expense during the last decade. " 04/25/1998 - "The poor efficacy of the mumps component of the MMR vaccine that has mainly been used in Switzerland is also evident. "
2.	VaccinesIBA 08/01/1995 - "This findings, combined with increasing vaccination coverage and the fact that 60% of mumps cases are reported in vaccinated people, suggests that the overall efficacy of the mumps vaccines used in Switzerland is probably below 80%. " 01/01/1996 - "These data support other recent reports which indicate an insufficient protective efficacy of current mumps vaccines." 12/01/1986 - "These results suggest that a live attenuated mumps and MRM vaccines are safe and effective in children with various underlying diseases." 08/01/1995 - "Further studies are needed to evaluate the efficacy of the different mumps vaccines used." 01/01/2014 - "Resurgent mumps outbreaks have raised questions about the current efficacy of mumps vaccines. "
3.	Mumps VaccineIBA 09/01/2014 - "The introduction of the mumps vaccine has dramatically reduced the number of mumps cases, but outbreaks have recently occurred among highly vaccinated populations in developed countries. " 02/05/2009 - "The live attenuated S(79) mumps vaccine can be effective in preventing clinical mumps outbreaks." 03/15/2008 - "Mumps is vaccine-preventable, and one dose of mumps vaccine is about 80% effective against the disease. " 05/08/1987 - "Sixty-three cases of clinical mumps occurring in a New Jersey school district presented an opportunity to determine compliance with the state's 1978 mumps "new entrants" school immunization law, investigate the effect of the law on the pattern of the outbreak, estimate the efficacy of mumps vaccine, and quantitate the economic impact of the outbreak. " 12/01/2013 - "This post-marketing mumps VE study found that immunization with one dose of the mumps vaccine confers partial protection against mumps disease. "
4.	AntigensIBA 05/12/1984 - "In addition, a lower mean absolute helper T cell count and an increased frequency of anergy to mumps intradermal antigen and of herpes simplex virus isolation distinguished these patients from those remaining in the cohort, who seem to be stable and in some cases to have improved." 06/01/2014 - "The results of this study and others suggest that two MMR doses confer optimal immunoresponses for all three antigens and the possible need for additional doses should be studied taking into account not only serological, but also epidemiological data, as there is no serological correlate of protection for mumps. " 05/01/2004 - "The aim of this study was to determine whether injection of the combination of Candida albicans, mumps, and Trichophyton skin test antigens was more efficacious than and as safe as single antigen injection. " 01/01/1986 - "Immunohistochemical studies revealed that viral antigen of HVJ was found in stria vascularis (6/11), Reissner's membrane (5/11), Organ of Corti (2/11) and viral antigen of mumps was found in stria vascularis (3/11), Reissner's membrane (1/11), Organ of Corti (1/11) in inoculated side of cochlea. " 06/01/1983 - "In this report studies were undertaken to determine whether LT induced by mumps skin test antigen (MSTA) correlated with skin test sensitivity. "
5.	Rubella VaccineIBA 09/01/2014 - "Though the move to introduce rubella vaccine in to the UIP is laudable, the decision to overlook mumps seems inexplicable and illogical. " 09/01/2001 - "National and local pilot programmes did not succeed to promote vaccination in countees with a low measle-mumps-rubella vaccine coverage. " 03/01/1999 - "In both groups, more than 90% of infants showed an immune response to the mumps and rubella vaccine strains at 14 months of age. " 06/01/1973 - "Occurrence following combined mumps-rubella vaccine." 07/01/1997 - "Eighty-three percent of those who thought the efficacy of measles, mumps, and rubella vaccine would not be affected by a URI recommended vaccination vs only 8% of physicians who thought efficacy would decrease (P < .001). "
6.	AntibodiesIBA 03/24/2011 - "Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy." 03/01/2009 - "A study of the age-specific seroprevalence of antibodies against mumps in children aged 3-18 years in Shahrekord aimed to establish the needof antibodies against mumps in children aged 3-18 years in Shahrekord aimed to establish the need for booster vaccinations to cover non-immune children. " 06/02/2008 - "The objective of the present study was to evaluate the seroprevalence of mumps antibodies in the Italian population, stratified by age, gender and geographical area. " 09/11/2006 - "We conducted a seroprevalence study of mumps antibodies among 353 Israeli military recruits aged 18-19, based on a representative sample of sera collected in 1999. " 04/01/1989 - "Japanese sera were shown by enzyme-linked immunosorbent assay (ELISA) to contain frequently antibodies against allantoic fluid, confirming the results obtained in our previous study on ELISA for the detection of mumps antibodies. "
7.	Immunoglobulin M (IgM)IBA 12/01/2011 - "IgM detection is considered as the gold standard for mumps diagnosis. " 10/01/2015 - "Since SVF does occur in highly vaccinated populations and IgM will not increase to detectable levels in all SVF patients, we strongly recommend using PCR plus serology tests to avoid false-negative diagnoses in vaccinated individuals with clinical signs of mumps. " 10/01/2015 - "IgM was more reliable with a longer time after onset of symptoms (67%), but indirect IgM serology was of insufficient sensitivity for vaccinated mumps cases (30%); the IgM μ-capture assay detected more cases in this group. " 02/01/2014 - "The sensitivity and specificity of the mumps IgM Liaison(®) assay were 88% and 95% respectively, with an inter-assay and intra-assay variation of 13.9% and 5.3% respectively. " 12/15/2013 - "Mumps IgM was detected in 17% of available specimens. "
8.	Attenuated VaccinesIBA 03/01/1997 - "The action of live attenuated vaccines against mumps is poorly understood although their clinical efficacy is beyond doubt. " 06/01/1990 - "Widespread use of safe and effective live attenuated vaccines has dramatically reduced the incidence of rubella, congenital rubella, and mumps in the United States. " 10/01/2002 - "The introduction of live attenuated vaccines, either singly or as the measles-mumps-rubella combined vaccine, has dramatically reduced the occurrence of disease and in countries where vaccine uptake is high, indigenous disease has been virtually eliminated. " 04/01/2008 - "It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. " 07/01/2005 - "Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial. "
9.	Immunoglobulin G (IgG)IBA 06/11/2007 - "The aim of this study was to describe and discriminate between primary and secondary vaccine failure in a highly vaccinated population for mumps using IgG avidity testing. " 09/30/2005 - "The aim of this study was to discriminate between primary and secondary vaccine failure in children with mumps using IgG avidity testing. " 10/13/2015 - "IgG levels were determined for mumps using 2 commercial tests of 2119 individuals aged 6-64 years. " 01/01/2015 - "A cross-sectional survey of mumps IgG in the general population of Jiangsu province was conducted in 2012 to gain comprehensive information on the immunity profile of the general population. " 01/01/2015 - "In contrast, the mumps-specific IgG and VN antibody concentrations of the previously vaccinated mumps cases were significantly higher within the first 2 months after onset of mumps and declined thereafter, characteristic for a secondary response. "
10.	Interferon-alpha (Interferon Alfa)FDA Link 01/01/1985 - "[Etiotropic therapy with human leukocyte interferon of the affected nervous system in mumps]." 07/01/1991 - "Four patients with bilateral mumps orchitis received systemic treatment with interferon-alpha 2B (3 X 10(6) IU/day) for 7 days. " 07/01/1991 - "Four patients with bilateral mumps orchitis received systemic treatment with interferon-alpha 2B (3 x 10(6) IU per day) for 7 days. " 01/01/1986 - "Alpha interferon which was acid labile was detected in the CSF of 89% and 63% respectively of patients with mumps and enterovirus meningitis." 07/01/1991 - "Systemic treatment with interferon-alpha 2B: an effective method to prevent sterility after bilateral mumps orchitis."

Therapies and Procedures

1.	Immunotherapy 05/01/2005 - "Intralesional immunotherapy using injection of Candida, mumps, or Trichophyton skin test antigens is an effective treatment for warts, as indicated by significantly higher response rates and distant response rates in subjects receiving antigen. " 05/01/2005 - "Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial." 05/01/2005 - "Intralesional immunotherapy using mumps, Candida, or Trichophyton skin test antigens has proved efficacy in the treatment of warts. " 05/01/2003 - "Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens." 04/01/2001 - "Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts."
2.	Intralesional Injections 05/01/2003 - "To determine the efficacy of intralesional skin test antigen injection for the treatment of resistant warts in children, we treated 47 pediatric patients with one or more warts with intralesional injection of mumps or Candida skin test antigen into one wart. " 05/01/2003 - "Intralesional injection of mumps and Candida skin test antigens has been shown to be effective in the treatment of warts. " 04/01/2001 - "Intralesional injection of mumps or Candida antigens into warts of immune individuals represents effective treatment. " 04/01/2001 - "Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts." 11/01/2014 - "Here we present two cases of MC that improved with measles, mumps, and rubella (MMR) vaccine intralesional injection. "
3.	Injections 08/01/2013 - "Measles-mumps-rubella (MMR) VC (2 injections) increased in 24- to 35-month-olds from 60.3% in 2008 to 81.0% in 2011. " 08/01/2005 - "Antibody responses to measles, mumps and rubella were >or=98%, similar to the control, after 1 or 2 injections of MMRV. " 04/01/2004 - "Vaccinations specifically aimed at eradicating rubella were begun with monocomponent vaccine in the mid-1970s, and the measles, mumps and rubella (MMR) vaccination programme with two injections got underway in 1982. " 11/01/2007 - "The availability of a combined vaccine against measles, mumps, rubella and varicella could allow an easier introduction of VZV prophylaxis in infants immunization schedules without increasing the number of injections and of accesses to Health Services." 07/01/2001 - "Following high-dose CT a minimal 12-months term and a normalization of the blood lymphocytes count is necessary before planning booster injections once having checked for antidiphteria, tetanic, polio, measles, mumps, rubella and +/- haemophilus antibody titles. "
4.	Aftercare (After-Treatment) 08/01/1998 - "After treatment, rates of seropositivity for measles antibody declined by 13% (90% of patients to 77%; P = .13); for mumps antibody, by 18% (97%-79%; P = .02); and for rubella antibody, by 21% (85%-64%; P = .03). " 08/01/2010 - "Seventy-seven patients with acute lymphoblastic leukemia (ALL) who were in complete remission and whose therapies had been stopped for at least 6 months before enrollment in this study were retrospectively analyzed regarding their antibody status for measles, mumps, and rubella, with the aim to demonstrate the seropositivity rate after treatment in the authors' group. " 12/01/2011 - "Anti- tetanus, diphtheria, mumps, measles, and rubella titers were measured before and after treatment by means of ELISA. " 10/01/2006 - "Regarding antibody titers after treatment, the number of children who had preserved the defined protection level for antibodies differed widely, ranging from 17 to 98% for diphtheria, 27 to 82% for Bordetella pertussis, 20 to 98% for tetanus, 62 to 100% for poliomyelitis, 35 to 100% for Haemophilus influenzae type B (HiB), 29 to 92% for mumps, 29 to 60% for measles and 72 to 92% for rubella. " 01/01/1960 - "[Modification of the receptivity of animal and human erythrocytes to influenza and mumps agglutinins after treatment of these erythrocytes with formol]."
5.	Plasmapheresis 12/01/1996 - "A polyneuropathy developed 18 days after the onset of mumps, that improved with plasmapheresis. "